Your browser doesn't support javascript.
loading
Psychotropic Medications Use among Children with Autism in Saudi Arabia.
Alenezi, Shuliweeh; Alnemary, Fahad; Alamri, Asma; Albakr, Dalal; Abualkhair, Lamees; Alnemary, Faisal.
Afiliação
  • Alenezi S; Department of Psychiatry, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia.
  • Alnemary F; Department of Special Education, College of Education, Taif University, Taif 21944, Saudi Arabia.
  • Alamri A; Department of Child Psychiatry, King Abdullah Specialist Children Hospital, Riyadh 14611, Saudi Arabia.
  • Albakr D; Department of Psychiatry, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
  • Abualkhair L; Department of Psychiatry, College of Medicine, King Saud University, Riyadh 11451, Saudi Arabia.
  • Alnemary F; Autism Center of Excellence, Riyadh 12713, Saudi Arabia.
Children (Basel) ; 9(7)2022 Jun 28.
Article em En | MEDLINE | ID: mdl-35883950
Psychotropic medication use is rising among children with autism spectrum disorders (ASD) in Saudi Arabia. Two hundred ninety-three parents of children diagnosed with ASD completed a parental concerns questionnaire (PCQ) online to examine children's family socio-demographics, health conditions and comorbidities, and past and current exposure to psychotropic medication as prescribed by their primary doctor. Findings revealed that more than one-third of the parents (39.08%) reported that their children were using medications at the time of the survey; risperidone (53%), methylphenidate (30%), and valproic acid (9%) were the most commonly used. A smaller number of parents stated that their children had previously used medications (16.09%). The most often prescribed drugs among this group were risperidone (45%), followed by methylphenidate (32%) and valproic acid (17%). The variables that showed a statistically significant association with the current use of psychotropic drugs were the child's age (OR = 1.25, 95% CI: 1.12, 1.40, p < 0.001), presence of comorbidities (OR = 7.75, 95% CI: 3.48, 17.24, p < 0.001), communication difficulties (OR = 1.79, 95% CI: 1.09, 2.95, p < 0.021), and anxiety symptoms (OR = 1.70, 95% CI: 1.00, 2.87, p < 0.049). Similarly, the child's age (OR = 1.23, 95% CI: 1.08, 1.40, p < 0.002) and presence of comorbidities (OR = 2.83, 95% CI: 1.16, 6.29, p < 0.022) showed statistically significant associations with previous use.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Children (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Arábia Saudita

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Children (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Arábia Saudita